← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
  1. Home
  2. COR
  3. P/E History
OverviewAnalysisPriceRevenueEarningsP/ERatiosDividendTargets

COR logoCencora, Inc. (COR) P/E Ratio History

Historical price-to-earnings valuation from 1995 to 2026

Current P/E
38.4
Overvalued
5Y Avg P/E
23.7
+62% vs avg
PE Percentile
90%
High
PEG Ratio
N/A
N/A
TTM EPS$8.32
Price$305.90
5Y PE Range11.6 - 40.6
Earnings Yield2.60%

Loading P/E history...

COR Valuation Context

How does the current P/E compare to historical and market benchmarks?

vs. 5Y Average
38.4vs23.7
+62%
Premium vs History
vs. Healthcare
38.4vs22.2
+73%
Above Sector
vs. S&P 500
38.4vs25.1
+53%
Above Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 6% EPS growth (1Y)
Export Data

P/E Ratio Analysis

As of May 6, 2026, Cencora, Inc. (COR) trades at a price-to-earnings ratio of 38.4x, with a stock price of $305.90 and trailing twelve-month earnings per share of $8.32.

The current P/E is 62% above its 5-year average of 23.7x. Over the past five years, COR's P/E has ranged from a low of 11.6x to a high of 40.6x, placing the current valuation at the 90th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.2x, COR trades at a 73% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 171.0x.

Relative to the broader market, COR commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our COR DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

COR P/E vs Peers

P/E ratio compared to closely matched public peers

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
MCK logoMCKMcKesson Corporation
$98B31.10.80+15%
CAH logoCAHCardinal Health, Inc.
$46B30.5-+87%Best
HSIC logoHSICHenry Schein, Inc.
$9B22.77.22+7%
CVS logoCVSCVS Health Corporation
$103B58.1--62%
UNH logoUNHUnitedHealth Group Incorporated
$330B27.5--15%
CI logoCICigna Corporation
$73B12.4Lowest-+83%
HCA logoHCAHCA Healthcare, Inc.
$96B15.10.72Best+29%
DGX logoDGXQuest Diagnostics Incorporated
$21B21.8-+14%

Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.

COR Historical P/E Data (1995–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterDatePriceTTM EPSP/E Ratiovs Avg
FY2026 Q1Wed Dec 31 2025 00:00:00 GM$337.75$8.3240.6x+26%
FY2025 Q4$312.53$7.9539.3x+22%
FY2025 Q3Mon Jun 30 2025 00:00:00 GM$299.85$9.7230.9x-5%
FY2025 Q2Mon Mar 31 2025 00:00:00 GM$278.09$8.6232.3x-0%
FY2025 Q1$224.68$7.0332.0x-1%
FY2024 Q4Mon Sep 30 2024 00:00:00 GM$225.08$7.5130.0x-7%
FY2024 Q3Sun Jun 30 2024 00:00:00 GM$225.30$9.2124.5x-24%
FY2024 Q2Sun Mar 31 2024 00:00:00 GM$242.99$9.1426.6x-18%
FY2024 Q1Sun Dec 31 2023 00:00:00 GM$205.38$9.1822.4x-31%
FY2023 Q4Sat Sep 30 2023 00:00:00 GM$179.97$8.5321.1x-35%
FY2023 Q3Fri Jun 30 2023 00:00:00 GM$192.43$8.2123.4x-27%
FY2023 Q2Fri Mar 31 2023 00:00:00 GM$160.11$7.7820.6x-36%

Average P/E for displayed period: 32.3x

Full COR Stock Analysis

Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.

View Analysis

See COR's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is COR Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare COR vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

COR — Frequently Asked Questions

Quick answers to the most common questions about buying COR stock.

Is COR stock overvalued or undervalued?

COR trades at 38.4x P/E, above its 5-year average of 23.7x. The 90th percentile ranking indicates a premium to historical valuation.

How does COR's valuation compare to peers?

Cencora, Inc. P/E of 38.4x compares to sector median of 22.2x. The premium reflects expected growth above peers.

What is COR's PEG ratio?

COR PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1995-2026.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

COR P/E Ratio History (1995–2026)

P/E ratio calculated as closing price divided by trailing 12-month diluted EPS at each quarter end.